Hydrogenics Corp (HYGS) 7.16 $HYGS NextEra Energy

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Hydrogenics Corp (HYGS) 7.16 $HYGS

NextEra Energy Partners Closes Purchase of 2 Wind Farms
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:04PM CDT
Shares of NextEra Energy Partners, LP (NEP)inched up 1.10% to close at $31.24 following its announcement of the acquisition of two wind farms from its parent company, NextEra Energy, Inc. (NEE).
HYGS: 7.16 (+0.28), NEE: 129.93 (+1.60), NEP: 30.86 (+0.30), GEVO: 0.54 (+0.01)

Hydrogenics Signs Development Agreement with Chinese Partner
GlobeNewswire - Wed Jun 08, 5:30AM CDT
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) a leading developer and manufacturer of hydrogen generation technology and hydrogen fuel cell power modules, today announced that it has entered into a strategic partnership agreement with SinoHytec, a vehicle propulsion technology company based in Beijing, for the delivery of fuel cells in China. The agreement consists of fuel cell power module co-development and the supply of power systems specifically designed for the Chinese market. The power systems will be integrated into buses and trucks from several leading vehicle manufacturers in China during 2016 and 2017, and the total value of the contract is approximately $13.5 million.
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Hydrogenics Announces Upcoming Investor Events
GlobeNewswire - Wed May 25, 5:30AM CDT
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company", a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that the Company will participate in the following investor events during June, 2016:
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Hydrogenics Announces Election of Directors
GlobeNewswire - Thu May 12, 5:30AM CDT
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company", a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that all of the nominees listed in the Management Proxy Circular dated March 21, 2016 were elected as directors of Hydrogenics Corporation at the Company's Annual General Meeting held on May 11, 2016 in Mississauga, Ontario, Canada.
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Hydrogenics reports 1Q loss
Automated Insights - Wed May 11, 5:40AM CDT
MISSISSAUGA, Ontario (AP) _ Hydrogenics Corp. (HYGS) on Wednesday reported a loss of $2.4 million in its first quarter.
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Hydrogenics Reports First Quarter 2016 Results
GlobeNewswire - Wed May 11, 5:30AM CDT
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company", a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today reported first quarter 2016 financial results. Results are reported in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Clean Energy Stocks Q1 Earnings Slated on May 11: CSIQ, HYGS
Zacks Equity Research - Zacks Investment Research - Tue May 10, 6:26AM CDT
Clean Energy stocks CSIQ and HYGS to report Q1 earnings on May 11
HYGS: 7.16 (+0.28), CSIQ: 15.03 (+0.19)

Hydrogenics Announces First Quarter Conference Call and Annual Meeting on May 11, 2016
GlobeNewswire - Mon Apr 25, 5:30AM CDT
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company", a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today announced that the Company will host a conference call at 1:00 p.m. Eastern on May 11, 2016 to review the fiscal first quarter ended March 31, 2016, following the Company's Annual Shareholder Meeting at 10 a.m. that same day. Earnings will be issued before the market opens, and the filing of the company's results with the appropriate regulatory bodies will follow.
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Will Hydrogenics (HYGS) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 8:35AM CDT
As of late, it has definitely been a great time to be an investor in Hydrogenics Corporation (HYGS)
HYGS: 7.16 (+0.28)

Hydrogenics Recognized at PwC Canada's 2016 Vision to Reality Innovator of the Year Awards
GlobeNewswire - Fri Apr 15, 5:30AM CDT
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG), a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, is pleased to announce that it has been named Innovator of the Year in the Builder (mid-market) category of PwC Canada's 2016 Vision to Reality Awards. This program recognizes outstanding Canadian companies that are leading the way in innovation, committed to creating and inspiring change and pushing boundaries to reshape their industry.
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Why Hydrogenics (HYGS) Could Be Positioned for a Surge
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 7:40AM CDT
Hydrogenics could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.
HYGS: 7.16 (+0.28)

Covanta Unit Buys Facility, Expands Southeast U.S. Presence
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 2:35PM CDT
Covanta's (CVA) unit acquired a material processing facility in Augusta, GA, and further expanded its operations in Southeast U.S.
HYGS: 7.16 (+0.28), CVA: 16.61 (+0.07), ORA: 43.92 (+0.66)

Why Hydrogenics (HYGS) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 7:55AM CDT
Hydrogenics (HYGS) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry
HYGS: 7.16 (+0.28)

Hydrogenics Reports Fourth Quarter and Full Year 2015 Results
GlobeNewswire - Wed Mar 09, 5:30AM CST
Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) ("Hydrogenics" or "the Company", a leading developer and manufacturer of hydrogen generation and hydrogen-based power modules, today reported fourth quarter and full year 2015 financial results. Results are reported in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).
HYGS: 7.16 (+0.28), HYG.TO: 9.39 (+0.44)

Should You Buy Hydrogenics (HYGS) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 7:35AM CST
Hydrogenics has earnings coming up pretty soon and events are shaping up quite nicely for its report
HYGS: 7.16 (+0.28)

Can Vanguard Natural Resources (VNR) Top Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 3:20PM CST
Upstream energy partnership Vanguard Natural Resources LLC (VNR) is set to release fourth-quarter 2015 results after the closing bell on Friday, Mar 4.
HYGS: 7.16 (+0.28), CSIQ: 15.03 (+0.19), SDPI: 1.85 (+0.05), VNR: 1.39 (+0.03)

Alt-Energy Stock Outlook - Jan 2016
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 2:40PM CST
Alt-Energy Stock Outlook - Jan 2016
HYGS: 7.16 (+0.28), YGE: 3.97 (+0.03), ORA: 43.92 (+0.66), JASO: 6.91 (+0.08), TSL: 8.25 (+0.24), SLTD: 2.44 (+0.01), SPWR: 14.92 (+0.48), CAFD: 15.81 (-0.05), CSIQ: 15.03 (+0.19), JKS: 19.48 (-0.25), SOL: 1.23 (+0.03), FSLR: 45.60 (+1.26), SCTY: 23.80 (-0.74), SUNE: 0.34 (unch), QTWW: 0.08 (-0.08)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 169

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 143

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 352

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 0

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 37

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 163

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading